BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Fenfen Wang†, Qin Chen‡, Genping Huang¹, Xuedong Guo¹, Na Li¹, Yang Li¹ and Baohua Li¹*

Abstract

Background: The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel (BKCa) plays an important role in regulating Ca (2+) signaling and cell physiological function, and is aberrantly expressed in some types of cancers. The present study focuses on identifying the oncogenic potential and clinical significance of BKCa in endometrial adenocarcinoma, as well as exploring the mechanistic relevance by 17β-estradiol (E2) inducing aberrant activation of MEK1/2 and ERK1/2 via BKCa.

Methods: The expression of BKCa, ERK1/2 and p-ERK1/2 were examined by immunohistochemical staining in 263 cases, including 185 primary types I endometrial cancer tissues, 38 atypical endometrial hyperplasia tissues and 40 normal endometrium tissues. Cell growth, cycle, apoptosis rate, migration and invasion was separately tested in Ishikawa cells using siRNA-BKCa and/or E2 treatment, as well as the expression of these interested proteins by western blot analysis.

Results: We showed that expression of BKCa is significantly elevated in 185 types I endometrial adenocarcinoma tissues compared to those of the normal endometrium and atypical endometrial hyperplasia tissues. Furthermore, in vitro observations revealed that down-regulation of BKCa expression inhibited cell growth by both enhancing apoptosis and blocking G1/S transition, suppressed cell migration and invasion in Ishikawa cells, and decreased the expression of p-MEK1/2 and p-ERK1/2. Additionally, RNAi-mediated knockdown of BKCa attenuated the increased cellular growth and invasion, as well as the elevated expression of p-MEK1/2 and p-ERK1/2 proteins, induced by E2 stimulation. More importantly, the aberrant expression of BKCa and p-ERK1/2 were closely related with poor prognostic factors in type I endometrial cancer, and up-regulated expression of p-ERK1/2 was significantly associated with shorter disease-free survival (DFS) and overall survival (OS) and was an independent prognostic factor in type I endometrial cancer patients.

Conclusion: Our results demonstrated that BKCa and the key downstream effectors p-ERK1/2 could be involved in important signaling pathways in initiation and development of endometrial adenocarcinoma and may provide a new therapeutic approach for women with endometrial cancer.

Keywords: Endometrial adenocarcinoma, BKCa, MEK1/2, ERK1/2, 17β-estradiol, Prognosis

* Correspondence: lbh19787@zju.edu.cn; lbh8888@163.com
† Fenfen Wang and Qin Chen contributed equally to this work.
¹ Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University, School of Medicine, Xueshi Road 1, Hangzhou, Zhejiang 310006, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Endometrial cancer (EC) is one of the most common malignancies of the female genital tract worldwide. It is grouped into two subtypes; type I, an estrogen-dependent endometrial adenocarcinoma which is associated with a slow progression and good prognosis, whilst type II is characterized as an aggressive non-estrogenic endometrial cancer with a poor prognosis. In general, type I is the most common endometrial cancer subtype [1].

Patients with EC are often diagnosed as early stage, and the best method to balance optimal survival with minimal adverse effects on quality of life has not yet been defined. The 5-year overall survival ranges from 74 to 91% in patients without metastatic disease [1], but the recurrence rate and mortality remains high [2]. Imbalance of estrogen and progesterone leading towards a hyper estrogenic state has been determined to increase the risk of endometrial adenocarcinoma. The mechanisms by which estrogen stimulates the endometrium from atypical endometrial hyperplasia to develop cancer are still unclear. Several studies have demonstrated that abnormal activation of PKCβ/ERK pathway [3], K-Ras/PKCβ [4], PI3K/AKT [5] induced by estrogen were involved in the process. However, the concrete mechanisms by which E2 induces the initiation and progression of endometrial adenocarcinoma have not been fully elucidated. The current study aimed to explore the mechanisms of E2 inducing type I endometrial carcinogenesis and cancerous development, and the related molecular pathway in order to identify a potential new approach for treatment.

The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel (BKCa) is encoded by the KCNMA1 gene and characterized by a large conductance to potassium, plays an important role in regulating Ca (2+) signaling and associates with cell membrane potential and cell metabolism [6, 7]. The altered expressions or activation of BKCa may lead to changes of intracellular calcium and membrane potential resulting in dysfunction of cells and organs. BKCa was revealed as an important molecule in regulating contraction/relaxation of muscle cells [8], neurotransmission in the brain, and metabolism, proliferation, migration, and gene expression [9]. Although it has been described in some types of cancer cell, such as osteosarcoma [10], breast cancer [11] and gastric cancer [12], little is known about the functions of BKCa in uterus. BKCa was studied in uterus smooth muscle and was reported that BKCa is over expressed in adenomyosis tissues, and it might cause abnormal muscle contractility that induces the inflammation effects, endometrium impairment and pain [13]. Moreover, the expression of BKCa in pregnant myometrium is reduced during labor and related with onset of parturition [14, 15]. Recently, Li et al. [16] reported the role of BKCa in endometrial cancer.
time point (0, 24, 48, and 72 h post-transfection), cells were incubated with CCK-8 (5 mg/mL) for 4 h at 37 °C and the absorbance read at 570 nm using a micro-plate reader. Each treatment was performed triplicates and each experiment was repeated twice.

Migration and invasion assay
Migration and invasion assays were carried out as described previously. For migration assays, 5 × 10⁵ cells suspended in 200 μl serum free medium were plated in the upper chamber and incubated at 37 °C for 12 h, while for the invasion assay, 9 × 10⁶ cells suspended in 300 μl serum free medium were plated in the upper chamber and incubated at 37 °C for 24 h. Non-invading or migrating cells were scrubbed with a cotton-tip swab and the cells that penetrated through the filter were stained with crystal violet and counted at a magnification of ×200 in randomly selected fields by using a phase-contrast microscope, and the mean number of cells per field was calculated.

Flow cytometry for cell cycle and apoptosis analysis
Flow cytometry was used to determine cell cycling progression and apoptosis analysis with procedure as described previously. For cell cycling analysis, at 48 h post-transfection, the cells (3 × 10⁵ cells/well) were collected by trypsinization and fixed with ice-cold ethanol (75%) at −20 °C for 24 h. Then, fixed cells were incubated in a propidium iodide/PBS staining buffer (20 μg/ml propidium iodide, 100 μg/ml RNase A, and 0.1% Triton X-100) at 37 °C for 30 min. Data were acquired using Cell Quest software, and the percentages of G0/G1, S, and G2/M phase cells were calculated. For cell apoptosis assays, at 48 h post-transfection of cells (3 × 10⁵ cells/well), Annexin-V and propidium iodide was added to the cells and samples were analyzed within 30 min after staining. Quantification of fluorescence was analyzed by flow cytometry.

Patients and immunohistochemical staining
The retrospective study enrolled 263 patients, including 185 primary type I endometrial cancer and 38 atypical endometrial hyperplasia tissues, with complete medical record information at Women’s Hospital of Zhejiang University, from January 2007 to December 2009. 40 patients with normal endometrial tissues that underwent the total hysterectomy because of gynecological benign diseases served as controls. The methods of tissue specimen preparation and immunohistochemistry staining performing were described previously [18]. BKCa, ERK1/2 and p-ERK1/2 immunoreactivities were assessed by staining intensity and positively stained distribution of the tumor cells. In brief, staining intensity was scored as negative (0), weakly positive (1), moderately positive (2) or strongly positive (3). The positively stained distribution was scored as 0 for < 0–5%, 1 for 6–25%, 2 for 26–50%, 3 for 51–75%, and 4 for > 75% positively stained cells. Finally, the intensity score and distribution score were multiplied to yield an overall score. A total score < 4 was considered as low expression and ≥ 4 as high expression.

Follow-up
The patients with type I endometrial cancer were followed up postoperatively by interview at the clinic or by phone call. Regional tumor recurrence, distant metastasis, and patient survival were recorded. Disease-free survival (DFS) and overall survival (OS) were calculated from the day of the surgery until disease recurrence or death. The last day of follow-up was December 2016. The mean follow-up was 94.7 months (range 14–120 months). There were 33 recurrences (33/185, 17.8%) and 30 deaths (30/185, 16.2%).

Statistical analysis
Statistics were assessed using software packages SPSS version 22.0. For in vitro experiments, a student’s t-test was used to analyze the differences between two groups. The results were presented as Mean ± SD. Correlations between protein expression and the clinic-pathological parameters and significant differences in protein expression were determined by Pearson’s chi-square test. Survival curves were generated by the Kaplan–Meier method and survival rates were compared using the log-rank test. On the univariate and multivariate analyses, the Cox proportional hazard method was used to identify independent predictors of survival. All statistical tests were two-sided, and p-values 0.05 were considered statistically significant (* < 0.05, ** < 0.01).

Results
Knockdown of BKCa expression influenced the biological effects of Ishikawa cells
To investigate the role of BKCa expression in initiation and progression of endometrial adenocarcinoma, we explored the effects of altered expression of BKCa on biological functions of Ishikawa cells. First, we knocked down the expression of BKCa using siRNA, and compared with the negative control. The siRNA targeting BKCa effectively down-regulated the mRNA and protein levels of BKCa at 48 h post-transfection (Fig. 1a, b). We also examined the effects on cellular proliferation using CCK-8 assay, which revealed that inhibition of BKCa expression reduced the proliferation of Ishikawa cells at 48 h and 72 h post-transfection (p = 0.035, p = 0.005) (Fig. 1c). Secondly, we observed that cell apoptosis was induced by inhibition of BKCa expression in Ishikawa cells as assessed by an Annexin V & PI apoptosis detection kit.
The inhibition of BKCa led to increased apoptotic response, and the apoptotic cell rate was significantly elevated compared to the control group \( (p = 2.4 \times 10^{-4}) \) (Fig. 1d). In consistent with apoptosis results, we simultaneously performed the cell cycle pattern by using PI staining and found that down-regulated expression of BKCa triggered a significant accumulation of cells in G1 phase and reduced the percentage of cells in S and G2/M phase \( (p = 2.8 \times 10^{-4}) \). FACS was used to analyze the alteration of cell cycle distribution induced by knockdown of BKCa expression. SiRNA targeting BKCa induced blocking of cell cycle progression and resulted in accumulation of G1 stage \( (p = 2.8 \times 10^{-4}) \). Representative images of migration and invaded cells following knockdown of BKCa expression in Ishikawa cells were showed by crystal violet staining. SiRNA targeting BKCa reduced significantly the numbers of migration \( (p = 3.18 \times 10^{-4}) \) and invaded \( (p = 0.001) \) cells. Data (Mean ± SD, \( n = 3 \) independent experiments).

**E2 induced the increase of BKCa expression in Ishikawa cells and promoted cell growth and invasion**

Estrogen-ER signaling pathways were found to be crucial for endometrial adenocarcinoma development, and as a
steroid hormone E2 was strongly related with the hormone dependent type I endometrial cancer. After stimulating with 1 nM E2, the proliferation of Ishikawa cells was increased significantly at 48 and 72 h \( (p = 0.019, p = 0.011) \) (Additional file 3: Figure S1B), and the rate of apoptosis was decreased when compared to the negative control \( (p = 0.006) \) (Additional file 3: Figure S1C). Additionally, E2 promoted cell cycle progression through G1 phase (Additional file 3: Figure S1D), and also enhanced the migration \( (p = 5.2E^{-5}) \) and invasive capacity \( (p = 4.87E^{-4}) \) of Ishikawa cells (Additional file 3: Figure S1E, F). The MEK/ERK pathways are important molecules in the process of E2 promoting endometrial adenocarcinoma, and the phosphated modifications of MEK1/2 and ERK1/2 are the main active forms for signal transduction. After exposure to 1 nM E2, the total proteins were extracted from the Ishikawa cells, and the interesting molecules were examined using western blot. We found that expression of BKCa protein \( (p = 0.013) \) was significantly up-regulated when compared to the control group. Importantly, the total MEK1/2 and ERK1/2 protein levels were unchanged, whereas the expression of p-MEK1/2 \( (p = 0.049) \) and p-ERK1/2 \( (p = 0.044) \) were elevated significantly in Ishikawa cells exposed to 1 nM E2 (Additional file 3: Figure S1A). It suggested that E2 could phosphorylate and active MEK/ERK pathway, leading to effects on a variety of physiologic and development processes in endometrial adenocarcinoma cells. More importantly, the molecular mechanism might be partly dependent regulation of BKCa.

Knockdown of BKCa attenuated up-regulation of MEK/ERK phosphorylation and promotion of Ishikawa growth and invasiveness induced by E2 stimulation

The possibility that BKCa is involved in the process of E2 activating MEK/ERK pathway is still unclear. To investigate the role of BKCa in the molecular mechanism induced by E2, we firstly knocked down the expression of BKCa in Ishikawa cells using siRNA technique, the mRNA and protein expression levels of BKCa were inhibited significantly, meanwhile decreased BKCa expression resulted in the reduction of phosphorylation of MEK1/2 \( (p = 2.96E^{-4}) \) and ERK1/2 \( (p = 0.001) \), no change of total MEK1/2 and ERK1/2 protein (Additional file 4: Figure S2A, B). The results showed that BKCa could regulate and activate MEK/ERK pathway in Ishikawa cells. Furthermore, we found that when E2 was used to stimulate the cell growth, the siRNA scramble control group demonstrated increased phosphorylation levels of MEK1/2 and ERK1/2 compared to that without E2 stimulation. However, down-regulation of BKCa with siRNA attenuated increased phosphorylation of MEK1/2 \( (p < 0.01) \) and ERK1/2 \( (p < 0.01) \) induced by E2 (Fig. 2a). This suggested BKCa may be an important middle membrane molecule in the process of E2 activating MEK/ERK pathway. Here, we have shown that BKCa plays an important role in growth and invasiveness of Ishikawa cells. When knockdown of BKCa expression using siRNA, that resulted in increased proliferation (Fig. 2b), migration and invasion in Ishikawa cells stimulated by E2 was all reversed accordingly (Fig. 2e, f) \( (p < 0.05) \). Moreover, the decreased apoptosis and the altered cell cycle distribution have been attenuated(Fig. 2c, d) \( (p < 0.01) \). This suggests that BKCa could be an essential middle molecular involved in E2 stimulating physiologic and development processes in Ishikawa cells via activating MEK/ERK pathway.

BKCa and p-ERK proteins closely related with clinicopathological characteristics and prognosis in 185 cases with type I endometrial cancer

We have shown that down-regulation of BKCa expression could induce a decrease in MEK1/2 and ERK1/2 phosphorylation in our study, and ERK was key effector in the pathway. Therefore, immunohistochemistry staining was performed to detect the proteins of BKCa, ERK1/2 and p-ERK1/2 in 263 endometrial tissue samples, including 185 type I endometrial cancer, 40 normal endometrial tissues and 38 atypical endometrial hyperplasia tissues. The detailed information of endometrial adenocarcinoma patients was shown in Additional file 5: Table S3.

The representative immunohistochemical staining of BKCa, ERK1/2 and p-ERK1/2 expression is shown in Fig. 3. The majority expressions of endometrial adenocarcinoma tissue showed consistent, strong staining of BKCa of cell membranous throughout all layers. BKCa expression was significantly elevated in endometrial adenocarcinoma tissues compared to those of normal endometrium \( (p = 8.4E^{-5}) \) and atypical endometrial hyperplasia \( (p = 1.39E^{-4}) \) (Table.1). There was no significant different in the expression levels of BKCa between the atypical endometrial hyperplasia tissue group and the normal endometrium tissues group \( (p > 0.05) \). As the key effector molecules on MEK/ERK pathway, the staining of ERK1/2 and p-ERK1/2 was predominantly located in the cytoplasm and nuclear of tumor cells, and they were both over-expressed in endometrial adenocarcinoma compared to normal endometrium \( (p = 4.19E^{-10}, p = 2.77E^{-8}) \) and atypical endometrial hyperplasia tissues \( (p = 1.97E^{-7}, p = 0.036) \) (Table.1). Between atypical endometrial hyperplasia group and normal endometrial group, only the expression of p-ERK1/2 was significantly increased in atypical endometrial hyperplasia \( (p = 0.001) \), and the expression of ERK1/2 showed no significant differences (Table.1). Further investigations about the correlations of the proteins and the clinico-pathological parameters were analyzed in endometrial adenocarcinoma group.
The Pearson chi-square test showed that expressions of ERK1/2 and p-ERK1/2 were positively correlated with BKCa expression \((p = 0.001, p = 0.038)\) (Table 2). The correlations between the three interested molecules and clinic-pathological parameters in 185 endometrial adenocarcinoma tissues were evaluated by Pearson’s chi-square test. The results from Table 3 showed that the elevated BKCa expression was significantly associated with FIGO stage \(\geq II\) \((p = 0.004)\) and lymph node metastasis (LNM) \((p = 0.011)\). Although ERK1/2 expression was not associated with any clinic-pathological characteristics, the high expression of p-ERK1/2 was significantly related to FIGO stage \(\geq II\) \((p = 0.012)\), cervical stromal involvement \((p = 0.014)\), LVSI \((p = 0.046)\) and LNM \((p = 0.018)\) (Table 3). It suggested that aberrant expression of BKCa and p-ERK1/2 was closely related with poor prognostic factors in type I endometrial cancer samples.

Kaplan–Meier analysis was used to investigate the prognostic value of the three proteins. The survival curves showed the association of expression of three...
proteins with disease-free survival (DFS) and overall survival (OS) in 185 type I endometrial cancer patients. Significance was tested in univariate and multivariate Cox regression models. Interestingly, the expressions of BKCa and ERK1/2 were not significantly associated with DFS or OS. Only up-regulated expression of p-ERK1/2 was significantly associated with shorter DFS ($p = 2.81 \times 10^{-4}$) and OS ($p = 4.18 \times 10^{-4}$) (Fig. 4). More importantly, univariate and multivariate analysis demonstrated that p-ERK1/2, which could act as downstream effector regulated by BKCa, was an independent prognostic factor of DFS ($p = 0.004$) and OS ($p = 0.008$) in type I endometrial cancer patients (Table 4). This suggests that BKCa and the key downstream effectors p-ERK1/2 could be involved in important signaling pathways in the pathogenesis and development of endometrial adenocarcinoma.

**Discussion**

In the present study, we investigated the role of BKCa in the initiation and development of endometrial adenocarcinoma. Our findings indicated that expression of BKCa in endometrial adenocarcinoma tissues were significantly increased compared to those of normal endometrium or atypical endometrial hyperplasia tissues. Additionally, we also found that knock down of BKCa expression in Ishikawa cells inhibited cell proliferation, migration and invasion, and promoted cell apoptosis, as well as blocking cell cycle progression. BKCa has been previously reported to be elevated in many kinds of cancer. BKCa is overexpressed in prostate cancer [19] and up-regulation of BKCa promotes proliferation, migration and invasion of prostate cancer cells. On the contrary, down-regulation of BKCa inhibited growth and metastasis of prostate cancer cells. BKCa was also hypothesized to function as oncoproteins in breast cancer [20], with metastatic breast cancer cells reported to exhibit increased BKCa activity, leading to greater invasiveness and migration [21]. Moreover, BKCa has been reported to act as a potential therapeutic target in breast cancer [22]. BKCa action was mainly mediated through forming a functional complex with alphavbeta3 integrin [19] or coupled with

| Proteins | Expression level | Endometrial adenocarcinoma (n = 185) | Atypical endometrial hyperplasia (n = 38) | Normal endometrium (n = 40) |
|----------|-----------------|--------------------------------------|------------------------------------------|-----------------------------|
| BKCa     | High            | 68                                   | 2                                        | 2                           |
|          | Low             | 117                                  | 36                                       | 38                          |
| ERK1/2   | High            | 110                                  | 5                                        | 2                           |
|          | Low             | 75                                   | 33                                       | 38                          |
| p-ERK1/2 | High            | 93                                   | 12                                       | 1                           |
|          | Low             | 92                                   | 26                                       | 39                          |
IP3R3 [23] to promote the BKCa activity. There are few studies exploring the relationship between BKCa and endometrial cancer. Recently using HEC-1-B cancer cell line to investigate the role of BKCa in endometrial cancer, Li et al. found that knock down of BKCa significantly inhibited HEC-1-B cell proliferation, migration and tumor growth in vitro and vivo assays [16]. Consistent with the previous reports, our results showed that the expression of BKCa in endometrial adenocarcinoma tissues were increased significantly, with decreased BKCa expression could inhibit cancer cell growth and invasion. It suggested BKCa could act as a potential oncogene in endometrial adenocarcinoma cells. Currently, the alteration and the precise oncogenic mechanisms of BKCa in endometrial adenocarcinoma cells remain unknown.

Accumulating evidence has also confirmed that E2 were important physiological and pathophysiological regulators of uterus and endometrial functions. Moreover, it has been apparent that MEK/ERK pathway is involved in the pathogenesis and development of endometrial cancer acting as the key molecular networkers [24]. E2 could promote the proliferation and stimulate the invasive

| Table 2 | The correlations of the expressions of ERK1/2, p-ERK1/2 and BKCa proteins in tissue samples of type I endometrial carcinoma |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
|          | ERK1/2 expression, n(%) | p-value | p-ERK1/2 expression, n(%) | p-value |
| BKCa, n(%) | Low | High |                            | Low | High |
| Low       | 58 (31.4) | 59 (31.9) | 66 (35.1) | 52 (28.1) |
| High      | 17 (9.2)  | 51 (27.6) | 27 (14.6) | 41 (22.2) |
| ERK1/2, n(%) | Low | High |                            | Low | High |
| Low       | 41 (22.2) | 34 (18.4) | 65 (35.1) | 57 (30.8) |
| High      | 51 (27.6) | 59 (31.9) | 32 (17.3) | 63 (34.1) |

| Table 3 | The correlations between the expressions of BKCa, ERK1/2 and p-ERK1/2 proteins and the clinicopathological parameters in 185 cases with type I endometrial cancer |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
|          | BKCa, n (%) | p-value | ERK1/2, n (%) | p-value | p-ERK1/2, n (%) | p-value |
| Characteristics | Low | High | Low | High | Low | High | Low | High |
| Age       | 0.119 | 0.151 | 0.179 |
| ≤ 60      | 82(44.3) | 40(21.6) | 54(29.2) | 68(36.8) | 65(35.1) | 57(30.8) |
| > 60      | 35(18.9) | 28(15.1) | 21(11.4) | 42(22.7) | 27(14.6) | 36(19.5) |
| FIGO stage | 0.004 | 0.271 | 0.012 |
| < II      | 80(43.2) | 32(17.3) | 49(26.5) | 63(34.1) | 64(34.6) | 48(25.9) |
| ≥ II      | 37(20.0) | 36(19.5) | 26(14.1) | 47(25.4) | 28(15.1) | 45(24.3) |
| Differentiation | 0.733 | 0.345 | 0.623 |
| Well/moderate | 92(49.7) | 52(28.1) | 61(33.0) | 83(44.9) | 73(39.5) | 71(38.4) |
| Poor      | 25(13.5) | 16(8.6)  | 14(7.6)  | 27(14.6) | 19(10.3) | 22(11.9) |
| Myometrial invasion | 0.958 | 0.066 | 0.201 |
| < 1/2     | 95(51.4) | 55(29.7) | 56(30.3) | 94(50.8) | 78(42.2) | 72(38.9) |
| ≥ 1/2     | 22(11.9) | 13(7.0)  | 19(10.3) | 16(8.6)  | 14(7.6)  | 21(11.4) |
| Cervical stromal involvement | 0.107 | 0.457 | 0.014 |
| No        | 84(45.4) | 41(22.2) | 53(28.6) | 72(38.9) | 70(37.8) | 55(29.7) |
| Yes       | 33(17.8) | 27(14.6) | 22(11.9) | 38(20.5) | 22(11.9) | 38(20.5) |
| LVSI      | 0.104 | 0.183 | 0.046 |
| No        | 112(60.5) | 60(32.4) | 72(38.9) | 100(54.1) | 89(48.1) | 83(44.9) |
| Yes       | 5(2.7)  | 8(4.3)   | 3(1.6)   | 10(5.4)  | 3(1.6)   | 10(5.4)  |
| LNM       | 0.011 | 0.407 | 0.018 |
| No        | 114(61.6) | 59(31.9) | 72(38.9) | 101(54.6) | 90(48.6) | 83(44.9) |
| Yes       | 3(1.6)  | 9(4.9)   | 3(1.6)   | 9(4.9)   | 2(1.1)   | 10(5.4)  |

FIGO International Federation of Gynecology and Obstetrics, LVSI lymph vascular space invasion, LNM lymph node metastasis
The capability of the endometrial cancer cell lines via the GPR30-mediated MEK/ERK pathway [25]. Autocrine motility factor (AMF) was related with the proliferative and metastatic of endometrial carcinoma and MEK-ERK1/2 pathway was involved [26]. As such, the MEK/ERK pathway may have a potential role in sustaining tumorigenic potential and radio-resistance in Ishikawa cells [27]. However, there are currently few reports about the relationship between estrogen and BKCa in E2 activating MEK/ERK pathway. In the study, we found that E2 increased the expression of BKCa protein, prompted cell growth and invasion, and induced the phosphorylation of MEK1/2 and ERK1/2 proteins. More importantly, the reduction of BKCa expression using siRNA in Ishikawa cells after E2 treatment could significantly attenuate the expression of p-MEK1/2 and p-ERK1/2 proteins, as well as cell growth and invasion capabilities induced by E2 stimulation, consequently suggesting that BKCa at least partially participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway. A previous report has shown that the G-protein coupled estrogen receptor 1 (GPER1) stimulation, that is activated by estrogen, could result in an increased BKCa channel activity. BKCa is directly activated by estrogens, which have an essential role in cancers of breast [28] and prostate through both genomic and non-genomic mechanisms. Estrogen at physiological concentration enhances BKCa channel activity through CGMP-PKG signaling pathway by stimulating generation of NO in vascular smooth muscle cells (VSMCs) [29]. Chronic exposure to estrogen also alters BKCa channel function in VSMCs. Estrogen could stimulate the transcriptional promoter activity of the same gene in mouse through activation of estrogen receptor α (ERα) [30] by binding to the estrogen responsive sequences in the promoter of mouse α-subunit gene. 17β-estradiol in an ex vivo tissue culture system augmented BKCa channel activity, which was accompanied by increased protein expression of β1 subunit [8], and the similar treatment of ovarectomized guinea pig increased expression of α subunit in aorta [31, 32]. However, on the contrary, exposure of cultured human coronary arterial myocytes to a pharmacological concentration of 17β-estradiol led to downregulation of BKCa channels [33]. Currently, the detailed mechanism about how estrogen mediated increase of BKCa is still not clear. It appears that estrogen augmented expression of BKCa is species specific or tissue dependent. Though we did not reveal the mechanism about E2 inducing elevated expression of BKCa in the current study, it may be similar to the previous studies.

Fig. 4 Kaplan–Meier curves showing the association of aberrant expression of BKCa, ERK1/2 and p-ERK1/2 with disease-free survival (DFS) and overall survival (OS) in 185 patients with type I endometrial cancer. High expression of p-ERK1/2 (c, f) was significantly associated with shorter DFS ($p = 2.81 \times 10^{-4}$) and OS ($p = 4.18 \times 10^{-4}$) in endometrial adenocarcinoma patients; in contrast, both BKCa and ERK1/2 expressions were not significantly associated with DFS or OS (a-e).
It is well established that the occurrence of endometrial adenocarcinoma is mainly stimulated by estrogen, and progresses slowly. The epithelium transforms from normal tissue through atypical endometrial hyperplasia to develop endometrial cancer. Atypical endometrial hyperplasia can be characterized as a pre-cancerous disease, and the majority of them progress to invasive disease if without effective clinical treatment. However, there is a current lack of biomarkers to predict progression to endometrial cancer. In the study, the data showed that the expressions of BKCa, ERK1/2 and p-ERK1/2 were significantly increased in endometrial adenocarcinoma compared to normal endometrium or atypical endometrial hyperplasia tissues. More importantly, only a gradual increase of p-ERK1/2 expression was observed beginning in normal endometrium and continuing through atypical endometrial hyperplasia to endometrial adenocarcinoma. Hence, Increased p-ERK1/2 expression closely related to clinical characteristics and might act as a potential biomarker to predict the occurrence of endometrial adenocarcinoma.

Table 4 Univariate and multivariate analysis of the correlations between prognostic value and disease-free and overall survival rates in 185 patients with type I endometrial cancer

| Characteristics                  | Disease-free survival |          | Overall survival |          |
|----------------------------------|-----------------------|----------|------------------|----------|
|                                  | HR 95% CI             | p        | HR 95% CI        | p        |
| Univariate analysis              |                       |          |                  |          |
| Age                              | 2.603 1.321–5.166     | 0.006    | 2.777 1.348–5.718 | 0.006    |
| FIGO stage                       | 2.956 1.454–6.011     | 0.003    | 3.420 1.600–7.312 | 0.002    |
| Differentiation                  | 5.221 2.628–10.375    | 2.39E−6  | 5.516 2.676–11.372 | 3.72E−6  |
| Myometrial invasion              | 4.911 2.477–9.738     | 5.17E−6  | 5.411 2.635–11.112 | 4.25E−6  |
| LVI                              | 6.352 2.940–13.722    | 2.55E−6  | 6.675 3.046–14.627 | 2.11E−6  |
| LNM                              | 14.51 6.994–30.103    | 6.79E−13 | 15.02 6.964–32.384 | 4.84E−12 |
| Cervical stromal involvement     | 1.589 0.797–3.170     | 0.188    | 1.932 0.942–3.959 | 0.072    |
| BKCa expression                  | 1.121 0.558–2.253     | 0.749    | 1.123 0.541–2.331 | 0.756    |
| ERK1/2 expression                | 0.594 0.300–1.175     | 0.134    | 0.546 0.267–1.120 | 0.099    |
| p-ERK1/2 expression              | 4.149 1.800–9.563     | 0.001    | 4.358 1.781–10.664 | 0.001    |
| Multivariate analysis            |                       |          |                  |          |
| Age                              | 1.717 0.842–3.503     | 0.137    | 1.912 0.909–4.025 | 0.088    |
| FIGO stage                       | 1.268 0.538–2.986     | 0.587    | 1.607 0.648–3.983 | 0.306    |
| Differentiation                  | 3.111 1.413–6.851     | 0.005    | 3.494 1.520–8.034 | 0.003    |
| Myometrial invasion              | 3.096 1.430–6.703     | 0.004    | 3.648 1.642–8.106 | 0.001    |
| LVI                              | 0.503 0.154–1.647     | 0.256    | 0.635 0.196–2.050 | 0.447    |
| LNM                              | 5.008 1.513–16.573    | 0.008    | 3.832 1.145–12.826 | 0.029    |
| p-ERK1/2 expression              | 3.912 1.542–9.927     | 0.004    | 3.796 1.415–10.180 | 0.008    |

FIGO International Federation of Gynecology and Obstetrics, LVI lymph vascular space invasion, LNM lymph node metastasis, HR hazard ratio, 95% CI 95% confidence interval.

It is well established that the occurrence of endometrial adenocarcinoma is mainly stimulated by estrogen, and progresses slowly. The epithelium transforms from normal tissue through atypical endometrial hyperplasia to develop endometrial cancer. Atypical endometrial hyperplasia can be characterized as a pre-cancerous disease, and the majority of them progress to invasive disease if without effective clinical treatment. However, there is a current lack of biomarkers to predict progression to endometrial cancer. In the study, the data showed that the expressions of BKCa, ERK1/2 and p-ERK1/2 were significantly increased in endometrial adenocarcinoma compared to normal endometrium or atypical endometrial hyperplasia tissues. More importantly, only a gradual increase of p-ERK1/2 expression was observed beginning in normal endometrium and continuing through atypical endometrial hyperplasia to endometrial adenocarcinoma. Hence, Increased p-ERK1/2 expression closely related to clinical characteristics and might act as a potential biomarker to predict the occurrence of endometrial adenocarcinoma.

Though the prognosis of early stage endometrial adenocarcinoma with primary surgical resection is relative good, improvement of the five-year survival rate is still the goal of the clinical members. We have known that several molecular alterations had been described in the different types of EC, and these genes involved in the important signaling pathways were key factors related with the prognosis of the disease. The most relevant altered pathways in EC, include PI3K/AKT/mTOR [24], RAS-RAF-MEK-ERK [34], Tyrosine kinase, WNT/β-Catenin [35], and TGF-β signaling pathways [36]. MEK/ERK pathway is also an important kinase involved in the signal transduction of endometrial carcinoma and act as key targets in many cancer biological target therapies. ERK, as a key effector in MEK/ERK pathway, can be phosphorylated and translocated into the nucleus that inducing activation of downstream transcriptional factors to participate in the regulation of growth, development and differentiation. On the other hand, the level of p-ERK was found to be closely related to the prognosis of gastric cancer, hepatic cancer, and colon cancer. Hence, p-ERK acts as a prognostic factors and key oncogenic gene in different type of malignant cancer, with previous studies reporting that the elevated expression of p-ERK was correlated with later stage, deeper invasion and poor differentiation in endometrial cancer [34]. In the study, we found that expressions of ERK1/2 and p-ERK1/2 were both positive correlated with the expression of BKCa in 185 cases with type I
endometrial cancer, and BKCa could regulate the expression of p-MEK1/2 and p-ERK1/2 to influence cell growth and invasion in endometrial cancer cells. The present study is the first time showed possible association of BKCa with MEK/ERK pathway in endometrial adenocarcinoma. In the study, though BKCa was not an independent prognostic factor, BKCa could regulate the expression of p-ERK1/2 that could serve as an independent prognostic predictor of shorter DFS and OS in endometrial adenocarcinoma patients by univariate and multivariate analysis. Taken together, we suggest that BKCa acts as an oncogenic activity membrane molecule and could regulate MEK/ERK pathway to participate in the initiation and development of endometrial adenocarcinoma and influence the prognosis and survival rate.

Conclusions
In summary, BKCa had been confirmed to be an essential membrane molecule acting as an oncogenic factor in endometrial adenocarcinoma cell and regulate the p-MEK1/2 and p-ERK1/2 proteins expression to participate in cell growth and invasion by E2 stimulation. Therefore, targeting BKCa by siRNA could effectively inhibit the activity of MEK/ERK pathway and attenuate the cellular behavior induced by E2 treatment. These novel findings promote a better understanding of the functions and mechanisms of BKCa in endometrial adenocarcinoma, and may provide a new approach for the treatment of endometrial adenocarcinoma patients.

Additional files

**Additional file 1:** Table S1. The information about the sequences. (DOCX 16 kb)

**Additional file 2:** Table S2. The information of the primary antibodies used in the studies. (DOCX 15 kb)

**Additional file 3:** Figure S1. 17β-estradiol (E2) induced an increase in the expression of BKCa in Ishikawa cells and promoted the cell growth and invasion. (A) Western Blot showed that 1 nM E2 treatment significantly increased level of BKCa protein (p = 0.013) and the phosphorylation of MEK1/2 (p = 0.049) and phosphorylation of ERK1/2 (p = 0.044) in Ishikawa cells, but had no effect on level of total MEK1/2 and ERK1/2. (B) Exposure to 1 nM E2 promoted cell proliferation rate at 48 h and 72 h in Ishikawa cells (p = 0.019, p = 0.011). (C) Apoptosis assay was performed to determine the early and late apoptotic rate induced by E2 treatment in Ishikawa cells. 1 nM E2 reduced the apoptosis rate from 3.11 ± 0.53% to 1.30 ± 0.26% (p = 0.008). (D) FACS was used to analyze the alteration of cell cycle distribution induced by E2 treatment. 1 nM E2 promoted cell cycle progression and induced increased percentage of cells in S phase and decreased number of cells of G1 and G2/M stage percent. (E, F) 1 nM E2 also increased the numbers of migration (p = 5.2E−4) and invaded (p = 4.8E−4) cells significantly in Ishikawa cells. Data (Mean ± SD, n = 3 independent experiments). (TIF 51687 kb)

**Additional file 4:** Figure S2. Knockdown of BKCa expression using siRNA significantly decreased the phosphorylation level of MEK1/2 (p = 2.9E−5) and ERK1/2 (p = 0.001) in Ishikawa, but had no effect on level of the total MEK1/2 and ERK1/2 expressions. (TIF 7103 kb)

**Additional file 5:** Table S3. The information about the tissue samples of the patients with type endometrial cancer and the related clinic-pathological parameters. (DOCX 16 kb)

**Abbreviations**
BKCa: The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel; DFS: Disease-free survival; E2: 17β-estradiol; EC: Endometrial cancer; ER: Estrogen Receptor; FIGO: The International Federation of Gynecology and Obstetrics; LNM: Lymph node metastasis; LVSI: Lymph vascular space invasion; OS: Overall survival

**Acknowledgements**
We thank pathologist CYZ for histological diagnoses of endometrial adenocarcinoma and tissue samples IHC. We thank XJC for technical assistance and JYM for flow cytometry.

**Availability of data and materials**
All data generated and/or analyzed during the current study are available from corresponding author on reasonable request.

**Authors’ contributions**
Study design: FFW, QC and BHL. Sample collection: QC, GPH and NL. Cellular experiments: FFW, GPH, NL, YL, XDG and BHL. Immunohistochemical experiments and data analysis were supported by National Natural Science Foundation of China (81672568). The data interpretation and writing of the manuscript were supported by the Medical and Health Science and Technology Plan Project of Zhejiang Province (2015KYA124).

**Ethics approval and consent to participate**
The present study was approved by the Institutional Review Board, Women’s hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China. All authors read and approved the final manuscript.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University, School of Medicine, Xueshi Road 1, Hangzhou, Zhejiang 310006, People’s Republic of China. 2Department of Pathology, Women’s Hospital, Zhejiang University, School of Medicine, Xueshi Road 1, Hangzhou, Zhejiang 310006, People’s Republic of China.

**Received:** 25 April 2018 **Accepted:** 31 October 2018

**Published online:** 16 November 2018

**References**
1. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094–108.
2. Sufi DF, Sufi Neto J, Albravos MS, Favero G. Lymphadenectomy in early stage endometrial cancer: a critical review of the current literature. Tumori. 2014;100:477–85.
3. Tong JS, Zhang QH, Wang ZB, Li S, Yang CR, Fu XQ, et al. ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS One. 2010;5:e15408.

4. Koo KH, Jeong WJ, Cho YH, Park JC, Min do S, Choi KY. K-Ras stabilization by estrogen via PKCdelta is involved in endometrial tumorigenesis. Oncotarget. 2015;6:21338–40.

5. Su T, Qu JJ, Wang K, Li BL, Zhao D, Zhu YP, et al. Cross-talk between p21-activated kinase 4 and ERAlpha signaling triggers endometrial cancer cell proliferation. Oncotarget. 2017;8:68083–94.

6. Hou S, Heinemann SH, Hoshi T. Modulation of BKCa channel gating by endogenous signaling molecules. Physiology (Bethesda). 2009;24:26–35.

7. Lu R, Alloua A, Kumar Y, Egballi M, Stefan E, Toro L. MAXK channel partners: physiological impact. J Physiol. 2006;570:65–72.

8. Hu XQ, Dasgupta C, Chen M, Xiao D, Huang X, Han L, et al. Pregnancy reprograms large-conductance Ca2+-activated K+ channel in uterine arteries: roles of ten-eleven translocation Methylcytoine dioxygenase 1-mediated active demethylation. Hypertension. 2017;69(6):1181–191.

9. Bloch M, Ousingisawat J, Simon R, Schratt P, Gasser TC, Mihatsch MJ, et al. KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene. 2007;26:255–34.

10. Cambi B, Rezzonico R, Vitale S, Rouziere-Dubois B, Dubois JM, Barthel P, et al. Siling of the heavy potassium channels in human osteosarcoma cells promotes tumorigenesis. Int J Cancer. 2008;123:365–71.

11. Oeggerli M, Tian Y, Ruiz C, Wilker B, Sauter G, Obermann E, et al. Role of KCNMA1 in breast cancer. PLoS One. 2012;7:e41664.

12. Ma G, Liu H, Hua Q, Wang M, Du M, Lin Y, et al. KCNMA1 cooperating with PTQ2 is a novel tumor suppressor in gastric cancer and is associated with disease outcome. Mol Cancer. 2017;16:46.

13. Shi JH, Jin L, Leng JH, Lang JH. Expression of potassium channels in uterine smooth muscle cells from patients with Adenomyosis. Chin Med J. 2016;129:2005–5.

14. Lorca RA, Prabagaran M, England SK. Functional insights into modulation of BKCa channel activity to alter myometrial contractility. Front Physiol. 2014;5:289.

15. Gao L, Cong B, Zhang L, Ni X. Expression of the calcium-activated potassium channel in upper and lower segment human myometrium during pregnancy and parturition. Reprod Biol Endocrinol. 2009;7:27.

16. Li N, Liu L, Li G, Xia M, Du C, Zheng Z. The role of BKCa in endometrial cancer HEC-1-B cell proliferation and migration. Gene. 2018;655:42–7.

17. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, et al. mIR-375 is down-regulated in squamous cervical cancer cell and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol. 2011;179:2580–8.

18. Li B, Shi H, Wang F, Hong D, Lu W, Xie X, et al. Expression of E2F-1 and -P and N cadherin and its clinical significance in cervical squamous cell carcinoma and precancerous lesions. PLoS One. 2016;11:e0155910.

19. Du C, Zheng Z, Li D, Chen L, Li N, Yi X, et al. BKCa promotes growth and metastasis of prostate cancer through facilitating the coupling between alpha/beta integrin and FAK. Oncotarget. 2016;7:40174–88.

20. Schickling BM, England SK, Aukin-Bums N, Norian LA, Leslie KK, Frieden-Korovkina VP. BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway. Oncol Rep. 2015;33:533–8.

21. Khaitan D, Sankpal UT, Wekslar B, Meister EA, Romero IA, Couraud PO, et al. Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer. 2009;9:258.

22. Du C, Chen L, Zhang H, Wang Z, Liu W, Xie X, et al. Caveolin-1 limits the contribution of BKCa channel to MCF-7 breast cancer cell proliferation and invasion. Int J Mol Sci. 2014;15:20706–22.

23. Mound A, Rodat-Despoix L, Bougman S, Ouadid-Adhouch H, Matatif F. Molecular interaction and functional coupling between type 3 inositol 1,4,5-trisphosphate receptor and BKCa channel stimulate breast cancer cell proliferation. Eur J Cancer. 2013;49:3738–51.

24. Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, et al. Endometrial carcinoma: specific targeted pathways. Adv Exp Med Biol. 2017;943:149–207.

25. He YY, Bai B, Yang YQ, Liu XL, Wan XP. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009;100:1051–61.

26. Li Y, Jia Y, Che Q, Zhou Q, Wang K, Wan XP. AMF/PGL-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. Oncotarget. 2015;6:26373–87.

27. Marampon F, Gavina GL, Popov VM, Scarselli L, Festuccia C, La Verghetto ME, et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol. 2014;44:285–94.

28. Ciofet G, Borowiec AS, Mariot P, Ouadid-Adhouch H, Matatif F. The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells. Mol Pharmacol. 2007;71:843–51.

29. Ambrosini ML, Favre J, Olivier P, Rodriguez C, Gao J, Thuillel C, et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation. 2007;116:2435–43.

30. Kundu P, Aloua A, Stefani E, Toro L. Regulation of mouse Sloe gene expression: multiple promoters, transcription start sites, and genomic action of estrogen. J Biol Chem. 2007;282:27478–92.

31. Jamali K, Naylor BR, Kelly MJ, Ronnekleiv OK. Effect of 17beta-estradiol on mRNAs expression of large-conductance voltage-dependent, and calcium-activated potassium channel alpha and beta subunits in Guinea pig. Endocrine. 2003;20:227–37.

32. Nishimura I, Ui-Tei K, Saigo K, Iihi H, Sakuma Y, Kato M. 17beta-estradiol at physiological concentrations augments Ca2+/activated K+ currents via estrogen receptor beta in the gonadotropin-releasing hormone neuronal cell line GT1-7. Endocrinology. 2008;149:774–82.

33. Korovkina VP, Brainard AM, Issnall P, Schmidt TJ, England SK, Estrold binding to maxi-K channels induces their down-regulation via proteasomal degradation. J Biol Chem. 2004;279:1217–23.

34. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohono S, Maida Y, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007;98:652–8.

35. Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P, et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 2014;74:5103–17.

36. Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, Dupont NC, Clark K, et al. Expression and clinical significance of the transforming growth factor-beta signalling pathway in endometrial cancer. Histopathology. 2011;59:63–72.